Literature DB >> 33415720

Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer.

Javad Farhadi1, Ladan Goshayeshi2, Alireza Motavalizadehkakhky3, Jamshid Mehrzad4, Hassan Mehrad-Majd5,6.   

Abstract

BACKGROUND/AIMS: Tripartite motif-containing 3 (TRIM3) is a member of the TRIM protein family which is known to be involved in development of numerous tumor types. However, the prognostic role of TRIM3 in gastric cancer (GC) remained to be clarified. The aim of this study was to evaluate the expression pattern and prognostic significance of TRIM3 gene and its relationship with β-catenin, CyclinD, and BCL2 expression in patients with GC.
METHODS: A total of 40 fresh primary gastric cancer tumors and their matched adjacent noncancerous tissues were selected from the First Affiliated Hospital of Mashhad University. Real-time quantitative RT-PCR was performed to evaluate differences in TRIM3 expression in GC and normal tissues. The correlation between TRIM3 expression level and patients' overall survival, some clinicopathological variables, and β-catenin, CyclinD, and BCL-2 genes expression level were also studied. Moreover, patients were divided in two groups according to the TRIM3 expression levels: low and high.
RESULTS: Compared to noncancerous tissues, TRIM3 expression in GC tissues was significantly increased (fold change = 1.58). Kaplan-Meier survival analysis revealed a significant difference of patient survival according to TRIM3 expression status (P = 0.012). Low TRIM3 expression was associated with shorter overall survival and was an independent predictor for poor prognosis in GC patients (HR, 1.25; 95%CI, 1.02-1.60; P = 0.045). Expression of TRIM3 was negatively correlated with expression of β-catenin, BCL-2, and CyclinD as genes for proliferation, apoptosis, and the cell cycle in GC patients.
CONCLUSIONS: This study demonstrates that decreased level of TRIM3 mRNA expression is associated with poor prognosis in patients with gastric cancer. TRIM3 may play a protective role in gastric cancer by relieving the effects of cancer progressive genes and could be considered for further investigations as a prognostic biomarker.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gastric cancer; Overall survival; Prognosis; TRIM3

Mesh:

Substances:

Year:  2021        PMID: 33415720     DOI: 10.1007/s12029-020-00563-0

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  5 in total

1.  miR-4513 promotes breast cancer progression through targeting TRIM3.

Authors:  Yongzhen Li; Huifang Zhu; Jianqiang Wang; Xinlai Qian; Na Li
Journal:  Am J Transl Res       Date:  2019-04-15       Impact factor: 4.060

Review 2.  Gastric cancer in Iran: epidemiology and risk factors.

Authors:  Reza Malekzadeh; Mohammad H Derakhshan; Zinab Malekzadeh
Journal:  Arch Iran Med       Date:  2009-11       Impact factor: 1.354

Review 3.  Risk Factors for Gastric Cancer: A Systematic Review

Authors:  Ali Reza Yusefi; Kamran Bagheri Lankarani; Peivand Bastani; Zahra Kavosi
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27

4.  The expression of Bcl-2 and BID in gastric cancer cells.

Authors:  Mariusz Gryko; Anna Pryczynicz; Konrad Zareba; Bogusław Kędra; Andrzej Kemona; Katarzyna Guzińska-Ustymowicz
Journal:  J Immunol Res       Date:  2014-02-19       Impact factor: 4.818

  5 in total
  3 in total

1.  Clinical significance of TRIM29 expression in patients with gastric cancer.

Authors:  Javad Farhadi; Jamshid Mehrzad; Hassan Mehrad-Majd; Alireza Motavalizadehkakhky
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

Review 2.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

3.  TRIM3 and TRIM16 as potential tumor suppressors in breast cancer patients.

Authors:  Mohammad Reza Roshanazadeh; Maryam Adelipour; Arash Sanaei; Hadi Chenane; Mojtaba Rashidi
Journal:  BMC Res Notes       Date:  2022-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.